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To reflect upon ten years of antiretroviral therapy 
(ART) rollout, one really should set the clock back 
a little further to see the massive impact of ART 
on our lives – for clinicians and patients alike. My 
own journey with HIV began in 1999 when, as a 
young doctor, I decided to venture into private practice with a local 
general practitioner (GP) while assessing my career prospects. A 
week into my new job, the GP went on a trip overseas, leaving me 
with the following pearls: ‘look after the HIV patients and don’t let 
any die before I get back’. I was terrified, as HIV had not formed 
an extensive part of the medical school curriculum when I trained, 
and while our exposure to such patients was considerable, we were 
taught that the only management options were palliative. 
So I had a baptism of fire, as the bulk of the practice patient load 
was HIV, and patients came from many corners of the Eastern Cape 
to our practice. Many GPs in the region at that time did not have 
the time or interest to manage these patients and were afraid of 
attracting stigma to their practices and driving away other patients. 
Mostly I think that they felt helpless and were not aware of what 
was happening in HIV medicine outside South Africa. They didn’t 
know that effective treatments were available, and that in the USA 
and Europe, hospital wards previously dedicated to caring for dying 
AIDS patients were closing down, because patients were living. 
HIV was becoming a chronic, manageable disease, and although 
compared to current treatments, they were more toxic and less 
tolerable, people were living with HIV. And so, when my partner 
returned from his trip, all his HIV patients were still alive, and I was 
filled with passion to learn more about HIV and treatment options. 
But they were the lucky ones, and not too long after that I lost my 
first patient to AIDS; unfortunately, the first of many.
Despite the availability of effective treatment, accessibility 
was still very limited at that time, as was expertise in ART. 
Antiretrovirals (ARVs) were expensive (triple ART regimens 
often costing up to several thousands of rands each month). 
Monitoring tests were expensive. Few medical aids covered HIV 
treatment, despite the evidence that even with the high cost of 
ART at the time, treating HIV was more cost-effective than the 
costs associated with managing opportunistic infections in very 
sick patients requiring hospital admission. ART was not available 
in the public sector, so was only an option for those few who could 
afford to buy medications and pay for the laboratory monitoring 
tests themselves, or those who had access to clinical trials. 
Despite the medications that existed, I still had patients being 
carried in on mattresses, stretchers, home-made wheelchairs made 
of garden chairs on tricycle wheels, and I still had to send many 
patients home with what was palliative care at best. One way of 
accessing treatment was through my involvement in clinical trials, 
to bypass the inadequacies of the prevailing system. I wanted to 
help as many patients as we could in this way. Consequently, we 
were seeing two ends of the spectrum: the patients enrolled in 
clinical trials were flourishing – they were gaining weight, feeling 
well and returning to work – while others continued to die. This 
dichotomy was very difficult to reconcile in my mind as a clinician 
wanting to help all my patients.  
More lives were lost due to the pervasiveness of AIDS denialism 
at that time. The strong stance taken by Thabo Mbeki not only 
prevented access to treatment, but also resulted in many of those 
accessing ART through clinical trials or other means stopping 
their treatment. The Treatment Action Campaign (TAC) was 
fighting battles on many fronts: demanding access to treatment; 
campaigning for pharmaceutical companies to make ARVs 
affordable; and debunking the myths of AIDS denialism – and 
their fortitude and perseverance prevailed. Finally, in 2004, ART 
was made available in the public sector. 
Fast-forward ten years to 2014. ART is available; treatment 
guidelines make provision for earlier initiation of treatment; the 
incidence of HIV is slowly declining; life expectancy has increased; 
and fewer babies are infected with HIV. South Africa has the biggest 
ARV programme in the world, with more than 2 million people 
receiving treatment. Now we have shifted from simply providing 
some treatment, to providing treatment that is easier to take in terms 
of toxicity as well as convenience. No longer are we merely trying to 
save lives – now we aim for quality of life as well as longevity, and 
our patients are growing old with us. We are watching them start 
families, and helping them to have children who are free of HIV. 
Now we are aiming for zero new infections, zero deaths and zero 
stigma related to HIV. We are making significant strides towards 
achieving what ten years ago seemed impossible. 
Yes we now have some great new drugs, with yet more in the 
pipeline. And yes, we have managed to build what is, without any 
doubt, the largest, most successful ARV treatment programme in 
the world. And yes, we will eventually resolve the logistical issues 
that result in stock-outs. And yet there are still patients who are 
presenting just as sick as those I was seeing when I first started 
treating HIV. They delay testing, or once tested, delay accessing 
treatment because they fear they will face discrimination and stigma. 
While we have made such great inroads towards zero new infections 
and zero deaths, we are not doing as well when it comes to zero 
stigma. Until we are able to temper and eliminate stigma, zero new 
infections and zero deaths will remain just beyond our grasp.  
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